<p>Mesoporous silica nanoparticles (MSNs) have emerged as promising carriers in drug delivery systems due to their high surface area, tunable pore structure, excellent chemical stability, and biocompatibility. However, their practical application is often hindered by premature drug leakage and limited targeting capability. To address these challenges, a hybrid nanocarrier was developed by coating MSNs with a lipid bilayer (ML) and subsequently with a chitosan-polyethylene glycol-folic acid copolymer (CPF), yielding CPF-coated ML nanoparticles (MLCPF). Characterization confirmed successful layer-by-layer assembly with nanoscale size, spherical morphology, positive surface charge, and good colloidal stability. Doxorubicin (DOX) was efficiently loaded into MLCPF (DOX@MLCPF), exhibiting pH-responsive release with slower drug release at neutral pH and faster release under acidic conditions. In vitro studies showed blank MLCPF was biocompatible, while DOX@MLCPF displayed stronger anticancer activity than free DOX. Confocal microscopy revealed efficient cellular uptake of CPF-functionalized nanoparticles. These findings suggest MLCPF as a promising platform for controlled and targeted cancer therapy.</p>